· faq
What FDA's new NGS guidance actually changes — and what it leaves to your judgment
The April 2026 draft guidance on NGS-based safety assessment for genome editing therapies finally codifies a lot of what reviewers were already asking for in pre-IND meetings. Here's what's new, what isn't, and where sponsors still have to make the call.